Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin76.5%-2.9pp77.7%-1.9pp81.3%+2.5pp79.6%-0.3pp79.4%+0.5pp
Returns
Return on invested capital5.2%-3.3pp6.6%-1.4pp8.8%+3.6pp10.7%+6.6pp8.5%+5.3pp
Efficiency
Asset turnover0.4×0.0×0.4×0.0×0.4×0.0×0.4×0.0×0.4×0.0×
Liquidity
Current ratio5.8×+0.3×5.2×-0.1×4.8×+0.6×5.6×+2.5×5.5×+2.8×
Leverage
Debt-to-equity0.2×+0.1×0.1×+0.1×0.1×0.0×0.1×-0.2×0.1×-0.2×
Net debt / EBITDA-3.8×-3.1×-1.2×+0.3×-0.9×-0.8×-0.7×-2.4×-0.6×-3.3×
Per Share
Book value per share$31.43+6.6%$30.84+7.2%$31.54+14.9%$30.58+16.0%$29.49+15.8%
Valuation
Market capitalization$10.86B-19.4%$11.42B-8.9%$10.4B-22.3%$10.49B-32.9%$13.49B-18.2%
Price / sales3.4×-1.2×3.5×-0.8×3.4×-1.5×3.4×-2.6×4.6×-2.1×
Price / book1.7×-0.6×1.9×-0.3×1.7×-0.8×1.7×-1.2×2.3×-0.9×
EV / EBITDA21.1×+2.8×20×0.0×14×-15.6×11.5×-32.1×18.3×-36.3×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are BioMarin Pharmaceuticals's profit margins?
BioMarin Pharmaceuticals (BMRN) runs a 76.5% gross margin and a 19.9% operating margin, with a 16.8% net margin.
Where do BioMarin Pharmaceuticals's ratios come from?
Every ratio is computed from BioMarin Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.